📰 Specific Health Problem News
Specific Health Problem News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Specific Health Problem. Real-time updates on events, politics, business and more.
December 14, 2023
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 -- Reneo...
December 14, 2023
The STRIDE study did not meet its primary or secondary efficacy endpoint
November 13, 2023
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 -- Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the...
September 8, 2023
The efficacy and safety of low-sodium oxybate remained stable or improved over 6 months in patients with idiopathic hypersomnia.
August 29, 2023
Poor quality of life and impaired functioning across many symptom domains were shown in participants in the Real World Idiopathic Hypersomnia Outcomes Study (ARISE).
August 8, 2023
The efficacy and safety of low-sodium oxybate remained stable or improved over 6 months in patients with idiopathic hypersomnia.
January 5, 2022
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind,...
January 5, 2022
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind,...
January 5, 2022
Treatment with Xywav resulted in clinically meaningful improvement in idiopathic hypersomnia symptoms, including excessive daytime sleepiness, sleep inertia and prolonged sleep duration with
May 27, 2021
Message : Required fields NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to MYCAPSSA ®. The data were shared as an oral presentation at the 3...